Karrou Marouan, Messaoudi Najoua, Assarrar Imane, Alla Achwak, Rouf Siham, Latrech Hanane
Department of Endocrinology-Diabetology and Nutrition, Faculty of Medicine and Pharmacy, Mohammed VI University Hospital Center, University of Mohammed 1st, Oujda, Morocco.
Laboratory of Epidemiology, Clinical Research and Public Health, Faculty of Medicine and Pharmacy, Mohammed VI University Hospital Center, University of Mohammed 1st, Oujda, Morocco.
Clin Med Insights Endocrinol Diabetes. 2023 Oct 31;16:11795514231208328. doi: 10.1177/11795514231208328. eCollection 2023.
Our study aimed to compare the efficacy of transdermal dihydrotestosterone and testosterone enanthate in treating idiopathic micropenis.
It's a comparative randomized study of 49 patients with idiopathic micropenis who are followed up in the Endocrinology-Diabetology and Nutrition Department of Mohammed VI University Hospital Center of Oujda, Morocco. The study was conducted from December 2019 to April 2021. All patients received a clinical examination including measurement of penis size before and after hormonal treatment. The patients were divided into two random groups, each group received a different drug, the first arm was treated with transdermal dihydrotestosterone (27 patients) and the second arm was treated with testosterone enanthate (22 patients). The Trial registration number was researchregistry7745.
The majority of the patients were children. The mean age was 9.7 ± 4.4 years. In the first arm, the mean penile size increased from -2.42 SD to -0.7 SD with a gain of 2.37 cm on average. In the second arm, the mean size increased from -2.48 SD to -0.69 SD, with a gain of 1.82 cm on average. The increase in penile size in the first arm was significantly greater than in the second arm ( = .008). No side effects were detected in both arms.
In the present study, we demonstrated the superiority of transdermal DHT compared to injectable exogenous testosterone in the treatment of idiopathic micropenis. According to the age subgroups, there was no significant difference between the 2 treatments in each age group.
我们的研究旨在比较经皮二氢睾酮和庚酸睾酮治疗特发性小阴茎的疗效。
这是一项对49例特发性小阴茎患者进行的比较性随机研究,这些患者在摩洛哥乌季达穆罕默德六世大学医院中心内分泌 - 糖尿病与营养科接受随访。研究于2019年12月至2021年4月进行。所有患者均接受临床检查,包括激素治疗前后阴茎大小的测量。患者被随机分为两组,每组接受不同药物治疗,第一组用经皮二氢睾酮治疗(27例患者),第二组用庚酸睾酮治疗(22例患者)。试验注册号为researchregistry7745。
大多数患者为儿童。平均年龄为9.7±4.4岁。在第一组中,阴茎平均大小从 -2.42标准差增加到 -0.7标准差,平均增加2.37厘米。在第二组中,平均大小从 -2.4标准差增加到 -0.69标准差,平均增加1.82厘米。第一组阴茎大小的增加明显大于第二组(P = .008)。两组均未检测到副作用。
在本研究中,我们证明了在治疗特发性小阴茎方面,经皮二氢睾酮比注射用外源性睾酮更具优势。根据年龄亚组分析,在每个年龄组中两种治疗方法之间没有显著差异。